OOIR: Observatory of International Research

Papers

(The median citation count of JACC: Cardiooncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Editorial Board	140
Full Issue PDF	133
Full Issue PDF	117
Full Issue PDF	110
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	108
Priorities in Cardio-Oncology	95
Cardiovascular Safety in Oncology Clinical Trials	90
Hormonal Therapy and Cardiovascular Health	77
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	69
Full Issue PDF	63
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	60
Atrial Fibrillation in Patients With Cancer	58
Epigenomics of Cardio-Oncology	57
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	56
Balancing Promise and Evidence	56
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	55
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	53
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies	52
Full Issue PDF	52
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD	50
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	49
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	48
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	46
Cardiac Risk Stratification Before Lung Cancer Radiation	46
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA	43

Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	43
Frailty	42
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms	39
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis	38
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	38
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)	37
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy	37
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-2019	35
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients	34
Editorial Board/Officers Page	34
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer	33
Cancer Immunotherapy Beyond Checkpoint Blockade	33
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer	32
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	31
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance	29
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors	29
Full Issue PDF	28
Editorial Board	28
Permissive Cardiotoxicity	28
TRASTUZUMAB CARDIOTOXICITY IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS IN MEXICO	27
SUCCESSFUL DIAGNOSIS AND SURGICAL RESECTION OF A PULMONIC SARCOMATOID CARCINOMA LACKING PET AVIDITY OR MALIGNANT APPEARING CMR TISSUE CHARACTERISTICS	27
Quality-of-Care Measures for Cardio-Oncology	27
Developing a Model for Cross-Institutional Educational Collaborations	25
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity	25
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity	24
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation	22
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research	21
Leveling Up	21
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	21
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy	21
Vascular Complications of Atrial Fibrillation in Patients With Cancer	20
Endothelin-1	20
JACC: CardioOncology	20
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	19
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer	19
Low QRS Voltages in Cardiac Amyloidosis	19
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy	19
A CHALLENGING CASE OF A LARGE RIGHT HEART MASS COMPLICATED BY COMPLETE HEART BLOCK	18
The United Kingdom’s First Cardio-Oncology Service	18
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge	18
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer	17
Assessing Silent Cardiotoxicity in Long-Term Lymphoma Survivors Treated With Radiotherapy	17
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction	17
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy	17
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients	17
CHA2DS2-VASc Score in Cardio-Oncology	16
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	16
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer	16
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity	16
Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent	16

Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity	16
Fluoropyrimidine Therapy in Gastrointestinal Cancer	15
How to Perform Hematopoietic Stem Cell Transplantation	15
To Adjudicate or Not Adjudicate	15
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors	15
Full Issue PDF	15
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction	15
Hearts on the Minds of Oncologists	15
Cancer Therapy–Related Cardiac Dysfunction	14
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy	14
Full Issue PDF	14
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity	14
Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors	14
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?	14
ABSTRACT WITHDRAWN	14
SEX DIFFERENCES IN ANTHRACYCLINE-TREATED CANCER SURVIVORS ASSESSED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING	14
Cardiovascular Considerations After Cancer Therapy	14
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors	14
Author Index	14
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	13
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors	13
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY	13
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	13
JACC: CardioOncology	13
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	13
PALLIATIVE RESECTION OF A CARDIAC SARCOMA	12
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT	12
Guiding Treatment With Recovered CTRCD	11
Navigating the Uncharted	11
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	11
(Less) Time and Energy	11
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction	11
Clinical Practice Guidelines in Cardio-Oncology	11
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	11
Cardiovascular Care After Cancer	11
Editorial Board/Officers Page	10
The Cause of Death in Patients With Cancer	10
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	10
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	10
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB	10
Reply	10
Addressing the Overlooked	10
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	10
Full Issue PDF	10
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN	10
Reply	10
Reply	10
Preventing Cancer Therapy–Related Cardiotoxicity	10
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy	9
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA	9
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	9
The ESC Cardio-Oncology Guidelines	9
Amyloid Cardiomyopathy	9
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation	9
Reply	9
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors	9
Reply	9
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	9
Assessing STEMI Outcomes in Patients With Cancer	8
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	8
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients	8
When Clot Is Tumor	8
Overcoming LGBTQI+ Disparities in Cardio-Oncology	8
Full Issue PDF	8
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	8
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category	8
Learning From Trials	8
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma	7
FIRST DOSE ORTHOSTATIC HYPOTENSION FOLLOWING DOCETAXEL AND GEMCITABINE INFUSION	7
Reply	7
Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer	7
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice	7
Cancer Diagnosis, Physical Activity, and Heart Disease Risk	7
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity	7
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy	7
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors	7
Reply	7
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients	7
Editorial Board	7
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	7

Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy	6
Pumping Up the Standards	6
Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes	6
Editorial Board	6
Incident Cancer in Heart Failure Patients and the Need for Additional Investigations	6
Reduced Thoracic Aortic Distensibility Upon Breast Cancer Diagnosis (WF-97415 and WF-98213)	6
Risk of Incident Heart Failure Among Young Adult Cancer Survivors	6
Melanoma Treatment	6
Physical Inactivity, Adverse Body Composition, and Cardiac Function in Breast Cancer Survivors	6
Immune Checkpoint Inhibitor Myocarditis and Cellular Rejection in Orthotopic Heart Transplant Recipients	6
Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis	6
Shared Mechanisms in Cancer and Cardiovascular Disease: S100A8/9 and the NLRP3 Inflammasome	6
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors	6
Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer	6
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis	6
Longitudinal Right Ventricular Systolic Function Changes in Breast Cancer Patients Treated With Cardiotoxic Cancer Therapy	6
Blood Pressure Lowering and Risk of Cancer	6
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey	6
Leukemia and Heart Disease	6
Full Issue PDF	6
Ablating Late Cardiovascular Events in Modern Hematopoietic Cell Transplantation	6
Mitigation of Doxorubicin Cardiotoxicity With Synergistic miRNA Combinations Identified Using Combinatorial Genetics en masse (CombiGEM)	6
MARANTIC ENDOCARDITIS - DIAGNOSTIC AND MANAGEMENT CHALLENGES	6
Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors	6
Reply	5
New Cardiotoxicity Risk Assessment Guidelines	5
The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer	5
Predictors of Atrial Fibrillation After Thoracic Radiotherapy	5
Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies	5
Potential and Pitfalls of Pharmacovigilance Databases in Oncology	5
Assessing the Certainty of Evidence on Efficacy and Safety of Anticoagulants for Cancer-Associated Thrombosis	5
Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification	5
Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT	5
AL Amyloidosis for Cardiologists	5
SARCOIDOSIS MIMICKING CARDIAC AMYLOIDOSIS: A CHALLENGING CONUNDRUM	5
Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors	5
Reply	5
Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis	5
Mediterranean Diet Is Associated With Lower All-Cause and Cardiovascular Mortality Among Long-Term Cancer Survivors	5
Editorial Board	5
Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults	5
Articulating the JACC Journals’ Direction in Times of Global Change	5
Cancer-Associated Venous Thromboembolism	5
Reply	4
Is Preventative Oophorectomy Safe?	4
Embracing the Power of the Polysocial Risk Score	4
How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis	4
Determinants of Impaired Peak Oxygen Uptake in Breast Cancer Survivors: JACC: CardioOncology Primer	4
Steroids in Immune Checkpoint Inhibitor Myocarditis	4
Arterial Thromboembolism in Patients With AF and CHA2DS2-VASc Score 0-2 With and Without Cancer	4
Editorial Board/ACC Officers Page	4
Probing the Anthracycline-Induced Myocardial Injury	4
ER-Specific Autophagy or ER-Phagy in Cardiac Myocytes Protects the Heart Against Doxorubicin-Induced Cardiotoxicity	4
Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors	4
Personalized Trastuzumab-Induced Cardiac Dysfunction Risk Stratification and Surveillance	4
More Data to Support a Cardiac-Oncologic Partnership	4
Cardiovascular Disease in Myeloproliferative Neoplasms	4
Full Issue PDF	4
Epidemiology and Antithrombotic Therapy for Cancer-Associated Arterial Thromboembolism in Japan	4
Editorial Board/Officers Page	4
Imaging-Based Obesity Assessment for Risk Factor Stratification and Prognostication in Malignancy	4
Editorial Board	4
Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib	4
Significance of Alectinib-Induced Bradycardia	4
Two Decades of Cardiac Amyloidosis	4
Exercise Training in Breast Cancer Survivors	4
Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities	3
Cardio-Oncology Care Delivery for All Patients With Cancer Within Academic and Community Settings	3
Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort	3
Synergistic miRNA Combinations Mitigate Doxorubicin-Induced Cardiotoxicity	3
Walk Your Way Out of Cardiovascular Risk	3
Editorial Board	3
Full Issue PDF	3
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions	3
Risk of Hematologic Malignancies in Patients With Acute Myocardial Infarction	3
Management of Amyloid Cardiomyopathy in Resource-Constrained Settings	3
Raise the Flag	3
How Common Is Pre-Existing Cardiovascular Disease in Cancer Patients	3
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies	3
The Potential Impact of the 2022 ESC Cardio-Oncology Guidelines on Clinical Practice in China	3
Immune Checkpoint Inhibitors in Cardiac Sarcoma	3
SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction	3
Full Issue PDF	3
How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk	3
Cardio-Oncology and Health Equity	3
Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies	3
Understanding Race, Genotype, and Socioeconomic Status in Transthyretin Amyloid Cardiomyopathy	3
Combat Doxorubicin Cardiotoxicity With the Power of Mitochondria Transfer	3
Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors	3
The Role of Healthy Lifestyle in Cancer Incidence and Temporal Transitions to Cardiometabolic Disease	3
Screening for Coronary Artery Disease in Cancer Survivors	3
CARDIOVASCULAR DISEASE RISK CONTROL IN SURVIVORSHIP: THE ROLE AND IMPLEMENTATION OF CARDIO-ONCOLOGY SERVICES	3
How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer	3
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity	3
Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome	3